Browse

Neurochemical Alterations in Methamphetamine-Dependent Patients Treated with Cytidine-5 `-Diphosphate Choline: A Longitudinal Proton Magnetic Resonance Spectroscopy Study

Cited 9 time in Web of Science Cited 16 time in Scopus
Authors
Yoon, Sujung J.; Lyoo, In Kyoon; Kim, Hengjun J.; Kim, Tae-Suk; Kim, Namkug; Renshaw, Perry F.; Lukas, Scott E.; Sung, Young Hoon
Issue Date
2010-04
Publisher
NATURE PUBLISHING GROUP
Citation
NEUROPSYCHOPHARMACOLOGY; Vol.35 5; 1165-1173
Keywords
cytidine-5 `-diphosphate cholineN-acetyl-aspartatemethamphetamine dependenceproton magnetic resonance spectroscopytreatment
Abstract
Cytidine-5`-diphosphate choline (CDP-choline), as an important intermediate for major membrane phospholipids, may exert neuroprotective effects in various neurodegenerative disorders. This longitudinal proton magnetic resonance spectroscopy ((1)H-MRS) study aimed to examine whether a 4-week CDP-choline treatment could alter neurometabolite levels in patients with methamphetamine (MA) dependence and to investigate whether changes in neurometabolite levels would be associated with MA use. We hypothesized that the prefrontal levels of N-acetyl-aspartate (NAA), a neuronal marker, and choline-containing compound (Cho), which are related to membrane turnover, would increase with CDP-choline treatment in MA-dependent patients. We further hypothesized that this increase would correlate with the total number of negative urine results. Thirty-one treatment seekers with MA dependence were randomly assigned to receive CDP-choline (n = 16) or placebo (n 15) for 4 weeks. Prefrontal NAA and Cho levels were examined using (1)H-MRS before medication, and at 2 and 4 weeks after treatment. Generalized estimating equation regression analyses showed that the rate of change in prefrontal NAA (p = 0.005) and Cho (p = 0.03) levels were greater with CDP-choline treatment than with placebo. In the CDP-choline-treated patients, changes in prefrontal NAA levels were positively associated with the total number of negative urine results (p = 0.03). Changes in the prefrontal Cho levels, however, were not associated with the total number of negative urine results. These preliminary findings suggest that CDP-choline treatment may exert potential neuroprotective effects directly or indirectly because of reductions in drug use by the MA-dependent patients. Further studies with a larger sample size of MA-dependent patients are warranted to confirm a long-term efficacy of CDP-choline in neuroprotection and abstinence. Neuropsychopharmacology (2010) 35, 1165-1173; doi: 10.1038/npp.2009.221; published online 30 December 2009
ISSN
0893-133X
Language
English
URI
http://hdl.handle.net/10371/78488
DOI
https://doi.org/10.1038/npp.2009.221
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Psychiatry (정신과학전공)Journal Papers (저널논문_정신과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse